Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iopamidol
Drug ID BADD_D01181
Description Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Indications and Usage Not Available
Marketing Status approved
ATC Code V08AB04
DrugBank ID DB08947
KEGG ID D01797
MeSH ID D007479
PubChem ID 65492
TTD Drug ID D0O2HQ
NDC Product Code 68225-077; 0270-1412; 68225-078; 68225-100; 0270-1315; 0270-1317; 0270-1411; 70436-126; 62331-006; 0270-1316; 68225-076; 0270-1314; 70436-124; 57876-222
UNII JR13W81H44
Synonyms Iopamidol | Jopamidol | Gastromiro | Iopamidol, (+-)-Isomer | Iopamidol, (R)-Isomer | Iopamidol, Sodium Salt, (S)-Isomer | Iopamiro | Isovue 370 | Niopam | Solutrast | Solutrast 370 | Solutrast Gastro | SQ 13,396 | B-15,000 | B 15,000 | B15,000 | B-15000 | B 15000 | B15000 | Isovue
Chemical Information
Molecular Formula C17H22I3N3O8
CAS Registry Number 60166-93-0
SMILES CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemorrhagic stroke17.08.01.011; 24.07.04.0140.007113%Not Available
Hallucination19.10.04.003--
Head discomfort17.02.05.0270.024186%Not Available
Headache17.14.01.001--
Heart disease congenital02.11.01.014; 03.07.07.001--Not Available
Hemiparesis17.01.04.0010.010670%
Hepatorenal syndrome20.01.03.012; 09.01.03.007--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.029876%
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.0030.189216%
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.001--Not Available
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.071134%Not Available
Hypotension24.06.03.0020.058330%
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Hypoxia22.02.02.0030.010670%
Infection11.01.08.002--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.019206%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.059041%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.055484%Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site urticaria23.04.02.003; 12.07.03.029; 10.01.06.003; 08.02.03.029--Not Available
Injection site vesicles23.03.01.024; 12.07.03.051; 08.02.03.0510.007113%Not Available
Injury12.01.08.004--Not Available
Irritability19.04.02.013; 08.01.03.011--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene